Recombinant human thyrotropins of the twenty-first century

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 12, 2004, Pages 2435-2440

  Szkudlinski, Mariusz W ^a  

^a Trophogen Inc   (United States)

Author keywords

Pharmacodynamics; Recombinant human TSH; Superactive analogues; Thyroid cancer

Indexed keywords

AMINO ACID; IODINE 131; RECOMBINANT PROTEIN; RECOMBINANT THYROTROPIN; THYROID HORMONE; THYROTROPIN; THYROTROPIN ALPHA SUBUNIT; THYROTROPIN BETA SUBUNIT; THYROTROPIN RECEPTOR; UNCLASSIFIED DRUG;

BINDING AFFINITY; CATTLE; CHO CELL; CLINICAL STUDY; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG RESEARCH; DRUG SAFETY; DRUG SYNTHESIS; DRUG UPTAKE; EDITORIAL; HUMAN; NONHUMAN; RECEPTOR AFFINITY; RODENT; STRUCTURE ACTIVITY RELATION; THYROID CARCINOMA; THYROID DISEASE; WILD TYPE;

DRUG THERAPY; HUMANS; RECEPTORS, THYROTROPIN; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; THYROID NEOPLASMS; THYROTROPIN;

EID: 10644275297     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.12.2435     Document Type: Editorial

References (32)

1. MARSHALL SA, LAZAR GA, CHIRINO AJ, DESJARLAIS JR: Rational design and engineering of therapeutic proteins. Drug Discov. Today (2003) 8(5):212-221.
2. GOURGIOTIS L, SKARULIS MC: Clinical uses of recombinant human thyrotropin. Expert Opin. Pharmacother. (2004) 5 12):2503-2514.
3. GROSSMANN M, WEINTRAUB BD, SZKUDLINSKI MW: Novel insights into the molecular mechanisms of human thyrotropin action: structural, physiological and therapeutic implications for the glycoprotein hormone family. Endocr. Rev. (1997) 18:476-501.
4. SZKUDLINSKI MW, FREMONT V, RONIN C, WEINTRAUB BW: Thyroid-stimulating hormone and thyroid-stimulating hormone receptor structure-function relationships. Physiol. Rev. (2002) 82 2):473-502.
5. LAPTHORN AJ, HARRIS DC, LITTLEJOHN A et al.: Crystal structure of human chorionic gonadotropin. Nature (1994) 369 455-461.
6. SZKUDLINSKI MW, GROSSMANN M, WEINTRAUB BD: Structure-function studies of human TSH: new advances in the design of glycoprotein hormone analogs. Trends Endocrinol. Metab. (2002) 7:277-286.
7. GROSSMANN M, SZKUDLINSKI MW, WONG R et al.: Substitution of the seatbelt region of the thyrotropin (TSH)-β subunit with the corresponding regions of choriogonadotropin or follitropin confers luteotropic, but not follitropic activity to chimeric TSH. J. Biol. Chem. (1997) 272:15532-15540.
8. SZKUDLINSKI MW, TEH NG, GROSSMANN M, TROPEA JE, WEINTRAUB BD: Engineering human glycoprotein hormone superactive analogues. Nat. Biotech. (1996) 14:1257-1263.
9. COLE ES, LEE K, LAUZIERE K, KELTON C et al.: Recombinant human thyroid stimulating hormone: development of a biotechnology product for detection of metastatic lesions of thyroid carcinoma. Biotechnology (1993) 11:1014-1024.
10. SZKUDLINSKI MW, THOTAKURA NR, BUCCI I et al.: Purification and characterization of recombinant human thyrotropin (TSH) isoforms produced by Chinese hamster ovary cells: the role of sialylation and sulfation in TSH bioactivity. Endocrinology (1993) 133 4):1490-1503.
11. EAST-PALMER J, SZKUDLINSKI MW, LEE J, THOTAKURA NR, WEINTRAUB BD: A novel, nonradioactive in vivo bioassay of thyrotropin (TSH). Thyroid (1995) 5(1):55-59.
12. WONDISFORD FE, USALA SJ, DECHERNEY GS et al.: Cloning of the human thyrotropin beta-subunit gene and transient expression of biologically active human thyrotropin after gene transfection. Mol. Endocrinol. (1988) 2(1):32-39.
13. MEIER CA, BRAVERMAN LE, EBNER SA et al.: Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (Phase I/II study). J. Clin. Endocrinol. Metab. (1994) 78 1):188-196.
14. LADENSON PW, BRAVERMAN LE, MAZZAFERRI EL et al.: Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N. Engl. J. Med. (1997) 337 13):888-896.
15. HAUGEN BR, PACINI F, REINERS C et al.: A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J. Clin. Endocrinol. Metab. (1999) 94(11):3877-3885.
16. UTIGER RD: Follow-up of patients with thyroid carcinoma. N. Engl. J. Med. (1997) 337(13):928-930.
17. ROBBINS RJ, CHON JT, FLEISHER M, LARSON SM, TUTTLE RM: Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? J. Clin. Endocrinol. Metab. (2002) 87(7):3242-3247.
18. EMERSON CH, TORRES MS: Recombinant human thyroid-stimulating hormone: pharmacology, clinical applications and potential uses. BioDrugs (2003) 17(1):19-38.
19. TAIEB D, JACOB T, ZOTIAN E, MUNDLER O: Lack of efficacy of recombinant human thyrotropin versus thyroid hormone withdrawal for radioiodine therapy imaging in a patient with differentiated thyroid carcinoma lung metastases. Thyroid (2004) 14(6):465-467.
20. WILLEY KP: An elusive role for glycosylation in the structure and function of reproductive hormones. Hum. Reprod. Update (1999) 5(4):330-355.
21. ROMMERTS FF, VAN LOENEN HJ, SCHIPPER I, FAUSER BC: FSH-receptor interactions and signal transduction: an alternative view. Follicle stimulating hormone: regulation of secretion and molecular mechanisms of action. Proceedings of the Symposium On The Regulation and Actions af Follicle Stimulating Hormone, Evanston, Illinois, USA (25-28 October 1990). Hunzicker-Dunn M, Schwartz NB (Eds), Serono Symposia, Norwell, MA, USA (2002):61-81.
22. FARID NR, SZKUDLINSKI MW: Minireview: structural and functional evolution of the thyrotropin receptor. Endocrinology (2004) 145(9):4048-4057.
23. GROSSMANN M, LEITOLF H, WEINTRAUB BW, SZKUDLINSKI MW: A rational design strategy for protein hormone superagonists. Nat. Biotechnol. (1998) 16(9):871-875.
24. LEITOLF H, TONG KP, GROSSMANN M, WEINTRAUB BD, SZKUDLINSKI MW: Bioengineering of human thyrotropin superactive analogs by site-directed 'lysine-scanning' mutagenesis. Cooperative effects between peripheral loops. J. Biol. Chem. (2000) 275(35 ):27457-27465.
25. KENAKIN T: Predicting therapeutic value in the lead optimization phase of drug discovery. Nat. Rev. Drug Discov. (2003) 2(6):429-438.
26. KENAKIN T: Drug efficacy at G protein-coupled receptors. Ann. Rev. Pharmacol. Toxicol. (2002) 42:349-379.
27. ROBBINS RJ, ROBBINS AK: Recombinant human thyrotropin and thyroid cancer management. J. Clin. Endocrinol. Metab. (2003) 88 5):1933-1938.
28. SILVA MN, RUBIO IG, ROMAO R et al.: Administration of a single dose of recombinant human thyrotrophin enhances the efficacy of radioiodine treatment of large compressive multinodular goitres. Clin. Endocrinol. (Oxf) (2004) 60(3):300-308.
29. SANTINI F, BOTTICI V, ELISEI R et al.: Cytotoxic effects of carboplatinum and eprubicin in the setting of an elevated serum thyrotropin for advance poorly differentiated thyroid cancer. J. Clin. Endocrinol. Metab. (2002) 87(9):4160-4165.
30. RIBELA MT, BIANCO AC, BARTOLINI P: The use of recombinant human thyrotropin produced by Chinese hamster ovary cells for the preparation of immunoassay reagents. J. Clin. Endocrinol. Metab. (1996) 81(1):249-256.
31. RINGEL MD, LADENSON PW, LEVINE MA: Molecular diagnosis of residual and recurrent thyroid cancer by amplification of thyroglobulin messenger ribonucleic acid in peripheral blood. J. Clin. Endocrinol. Metab. (1998) 83(12):4435-4442.
32. KAKINUMA A, CHAZENBALK GD, JAUME JC et al.: The human thyrotropin (TSH) receptor in a TSH binding inhibition assay for TSH receptor autoantibodies. J. Clin. Endocrinol. Metab. (1997) 82 7):2129-2134.